Drug resistance, serotypes, and phylogenetic groups among uropathogenic Escherichia coli including O25-ST131 in Mexico City

Journal of Infection in Developing Countries

Volumn 5, Issue 12, 2011, Pages 840-849

  Molina López, José ^a,b   Aparicio Ozores, Gerardo ^a   Ribas Aparicio, Rosa María ^a   Gavilanes Parra, Sandra ^b   Chávez Berrocal, María E ^b   Hernández Castro, Rigoberto ^c   Angel Manjarrez Hernandez H ^b  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Adscrita Servicio de Fototerapia Hospital General Dr Manuel Cea González Secretaría de Salud   (Mexico)

Author keywords

Multidrug resistance; O25 ST131; Urinary infection; Uropathogenic Escherichia coli

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CARBENICILLIN; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; NALIDIXIC ACID; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CONTROLLED STUDY; MEXICO; MULTIDRUG RESISTANCE; NONHUMAN; PHYLOGENY; REVIEW; SEROTYPE; UROPATHOGENIC ESCHERICHIA COLI; UROPATHOGENIC ESCHERICHIA COLI O25 H4; UROPATHOGENIC ESCHERICHIA COLI O25 ST131;

EID: 84155174786     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.1703     Document Type: Review

References (47)

1. Foxman B, Brown P (2003) Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 17: 227-241.
2. Griebling TL (2007) Urinary Tract Infections in Women. In: Litwin MS, Saigal CS, editors. Urologic Diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC. 587-620.
3. Hooton TM, Stamm WE (1997) Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 11: 551-581.
4. Kodner CM, Thomas Gupton EK (2010) Recurrent urinary tract infections in women: diagnosis and management. Am Fam Physician 82: 638-643.
5. Harding GK, Ronald AR (1994) The management of urinary infections; what have we learned in the past decade? Int J Antimicrob Agents 4: 83-88.
6. Bours PH, Polak R, Hoepelman AI, Delgado E, Jarquin A, Matute AJ (2010) Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines. Int J Infect Dis 14: e770-e774.
7. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, Ferech M; European Antimicrobial Resistance Surveillance System Group; European Surveillance of Antimicrobial Consumption Project Group (2008) Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 14: 1722-1730.
8. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18: 657-686.
9. Manges AR, Tabor H, Tellis P, Vincent C, Tellier PP (2008) Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections. Emerg Infect Dis 14: 1575-1583.
10. Phillips I, Eykyn S, King A, Gransden WR, Rowe B, Frost JA, Gross RJ (1988) Epidemic multiresistant Escherichia coli infection in West Lambeth Health District. Lancet 1: 1038-1041.
11. Prats G, Navarro F, Mirelis B, Dalmau D, Margall N, Coll P, Stell A, Johnson JR (2000) Escherichia coli serotype O15:K52:H1 as a uropathogenic clone. J Clin Microbiol 38: 201-209.
12. Whittam TS, Ochman H, Selander RK (1983) Multilocus genetic structure in natural populations of Escherichia coli. Proc Natl Acad Sci U S A 80: 1751-1755.
13. Clermont O, Bonacorsi S, Bingen E (2000) Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 66: 4555-4558.
14. Johnson JR, Kuskowski MA, O'Bryan TT, Maslow JN (2002) Epidemiological correlates of virulence genotype and phylogenetic background among Escherichia coli blood isolates from adults with diverse-source bacteremia. J Infect Dis 185: 1439-1447.
15. Nicholas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Caniça MM, Park YJ, Lavigne JP, Pitout J, Johnson JR (2008) Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 61: 273-281.
16. Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, Baquero F, Cantón R, Nordmann P (2008) Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 14: 195-200.
17. Johnson JR, Johnston B, Clabots C, Kuskowski Ma, Castanheira M (2010) Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 51: 286-294.
18. Arredondo-García JL, Amábile-Cuevas CF (2008) High resistance prevalence towards ampicillin, co-trimoxazole and ciprofloxacin, among uropathogenic Escherichia coli isolates in Mexico City. J Infect Dev Ctries 2: 350-353.
19. Guajardo-Lara CE, Gonzáles-Martínez PM, Ayala-Gaytán JJ (2009) Resistencia antimicrobiana en la infección urinaria por Escherichia coli adquirida en la comunidad.¿Cuál antibiótico voy a usar? Salud Publica Mex 51: 155-158.
20. Amábile-Cuevas C (2010) Antibiotic resistance in Mexico: a brief overview of the current status and its causes. J Infect Dev Ctries 4: 126-131.
21. Wilson ML, Gaido L (2004) Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis 38: 1150-1158.
22. Carridge JE, Johnson JR, Pezzlo MT (1988) Laboratory diagnosis of urinary tract infections. In: Weissfeld AS, editor. Cumitech 2B. Washington: ASM Press. p. 2-19.
23. Ørskov F,Ørskov I (1984) Serotyping of Escherichia coli. In: Methods in Microbiology 14: 43-112. Edited by T. Bergan. London: Academic Press.
24. Ewing WH. (1986) Edwards and Ewinǵs Identification of Enterobacteriaceae. New York: Elsevier.
25. Scheutz F, Cheasty T, Woodward, Smith HR (2004). Designation of O174 and O175 to temporary O groups OX3 and OX7, and six new E. coli O groups that include verocytotoxin producing E. coli (VTEC): O176, O177, O178, O179, O180 and O181. APMIS 112: 569-584.
26. CLSI. (2010) Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. CLSI M100-S20-U. Wayne, PA: Clinical and Laboratory Standards Institute.
27. Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, Mulvey MR, Nordmann P, Ruppé E, Sarthou JL, Frank T, Vimont S, Arlet G, Branger C, Woodford N, Denamur E (2009) Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother.64: 274-277.
28. Lau SH, Reddy S, Cheesbrough J, Bolton FJ, Willshaw G, Cheasty T, Fox AJ, Upton M (2008) Major uropathogenic Escherichia coli strain isolated in the northwest of England identified by multilocus sequence typing. J Clin Microbiol 46: 1076-1080.
29. Peirano G, Pitout JD (2010) Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 35: 316-321.
30. Kaper JB, Nataro JP, Mobley HLT (2004) Pathogenic Escherichia coli. Nat Rev Microbiol 2: 123-14029.
31. Johnson JR (1991) Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 4: 80-128.
32. Mitsuda T, Muto T, Yamada M, Kobayashi N, Toba M, Aihara Y, Ito A, Yokota S (1998) Epidemiological study of a food-borne outbreak of enterotoxigenic Escherichia coli O25:NM by pulsed-field gel electrophoresis and randomly amplified polymorphic DNA analysis. J Clin Microbiol 36: 652-656.
33. Ansaruzzaman M, Bhuiyan NA, Begum YA, Kühn I, Nair GB, Sack DA, Svennerholm AM, Qadri F (2007) Characterization of enterotoxigenic Escherichia coli from diarrhoeal patients in Bangladesh using phenotyping and genetic profiling. J Med Microbiol 56: 217-222.
34. Deetz TR, Evans DJ, Evans DG, DuPont HL (1979) Serologic responses to somatic O and colonization-factor antigens of enterotoxigenic Escherichia coli in travellers. J Infect Dis 140: 114-118.
35. Picard B, Sevali J, Gouriou S, Duriez P, Brahimi N, Bingen E, Elion J, Denamur E (1999) The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect Immun 67: 546-553.
36. Johnson JR, Kuskowski MA, Gajewski A, Sahm DF, Karlowsky JA (2004) Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001. J Infect Dis 15: 1739-1744.
37. Cherifi A, Contrepois M, Picard B, Goullet P, de Rycke J, Fairbrother J, Barnouin J (1990) Factors and markers of virulence in Escherichia coli from human septicemia. FEMS Microbiol Let 70: 279-283.
38. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A (2008) European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 46: 2605-2612.
39. Leflon-Guibout V, Blanco J, Amaqdouf K, Mora A, Guize L, Nicolas-Chanoine MH (2008) Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 46: 3900-3905.
40. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF (2002) Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 46: 2540-2545.
41. Vasquez Y, Lee Hand W (2004) Antibiotic susceptibility patterns of community-acquired urinary tract infection isolates from female patients on the US (Texas)-Mexico border. J Appl Res 4: 321-326.
42. Gordon KA, Jones RN; SENTRY Participant Groups (Europe, Latin America, North America) (2003) Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 45: 295-301.
43. Echols RM, Tosiello RL, Haverstock DC, Tice AD (1999) Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis 29:113-119.
44. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE (1999) Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 29: 745-758.
45. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, Johnson J, Noreddin A, Low DE, Karlowsky JA; for the NAUTICA Group, Hoban DJ (2006) Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 27: 468-475.
46. Puerto AS, Fernandez JG, del Castillo Jde D, Pino MJ, Angulo JP (2006) In vitro activity ofβ-lactam and non-β-lactam antibiotics in extended-spectrumβ-lactamase-producing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis 54: 135-139.
47. Garau J (2008) Other antimicrobials of interest in the era of extended-spectrumß-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 14: 198-202.